OTLK
Income statement / Annual
Last year (2025), Outlook Therapeutics, Inc.'s total revenue was $1.41 T,
and the percentage change from the previous year is not available.
In 2025, Outlook Therapeutics, Inc.'s net income was -$62.42 T.
See Outlook Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
09/30/2025 |
09/30/2024 |
09/30/2023 |
09/30/2022 |
09/30/2021 |
09/30/2020 |
09/30/2019 |
09/30/2018 |
09/30/2017 |
09/30/2016 |
| Operating Revenue |
$1.41 T |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$8.15 M |
$3.09 M |
$3.81 M |
$2.98 M |
| Cost of Revenue |
$1.36 T
|
$113.86 K
|
$44.19 K
|
$204.69 K
|
$262.14 K
|
$554.07 K
|
$23.81 M
|
$18.50 M
|
$23.81 M
|
$0.00
|
| Gross Profit |
$57.21 B
|
-$113.86 K
|
-$44.19 K
|
-$204.69 K
|
-$262.14 K
|
-$554.07 K
|
-$15.66 M
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.04
|
0
|
0
|
0
|
0
|
0
|
-1.92
|
0
|
0
|
0
|
| Research and Development Expenses |
$27.18 T
|
$41.76 M
|
$26.45 M
|
$42.33 M
|
$38.96 M
|
$26.34 M
|
$23.81 M
|
$18.50 M
|
$23.81 M
|
$32.76 M
|
| General & Administrative Expenses |
$0.00
|
$29.94 M
|
$26.67 M
|
$20.74 M
|
$12.77 M
|
$9.97 M
|
$9.37 M
|
$14.23 M
|
$15.88 M
|
$21.56 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$39.94 T
|
$29.94 M
|
$26.67 M
|
$20.74 M
|
$12.77 M
|
$9.97 M
|
$9.37 M
|
$14.23 M
|
$15.88 M
|
$21.56 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
-$205.00 K
|
$0.00
|
-$1.90 M
|
$11.27 M
|
$0.00
|
-$23.81 M
|
$0.00
|
| Operating Expenses |
$67.12 T
|
$71.70 M
|
$53.13 M
|
$62.87 M
|
$51.73 M
|
$34.42 M
|
$44.45 M
|
$32.73 M
|
$39.69 M
|
$21.56 M
|
| Cost And Expenses |
$68.48 T
|
$71.70 M
|
$53.13 M
|
$63.07 M
|
$51.73 M
|
$36.84 M
|
$44.45 M
|
$32.73 M
|
$39.69 M
|
$54.33 M
|
| Interest Income |
-$89.74 B
|
$906.15 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$283.13 B
|
$3.16 M
|
$1.56 M
|
$1.49 M
|
$936.13 K
|
$1.76 M
|
$3.47 M
|
$3.89 M
|
$5.63 M
|
$1.85 M
|
| Depreciation & Amortization |
$0.00
|
$113.86 K
|
$44.19 K
|
$204.69 K
|
$262.14 K
|
$554.07 K
|
$3.36 M
|
$3.05 M
|
$2.69 M
|
$2.39 M
|
| EBITDA |
-$67.06 T |
-$72.09 M |
-$57.38 M |
-$64.36 M |
-$51.51 M |
-$36.20 M |
-$31.11 M |
-$26.80 M |
-$30.03 M |
-$48.95 M |
| EBITDA Ratio |
-47.44
|
0
|
0
|
0
|
0
|
0
|
-3.82
|
-8.68
|
-7.88
|
-16.43
|
| Operating Income Ratio |
-47.44
|
0
|
0
|
0
|
0
|
0
|
-4.46
|
-9.6
|
-9.41
|
-17.23
|
| Total Other Income/Expenses Net |
$3.08 T
|
-$3.66 M
|
-$5.85 M
|
-$2.98 M
|
-$1.43 M
|
-$1.67 M
|
-$1.64 M
|
-$4.10 M
|
-$2.47 M
|
-$1.85 M
|
| Income Before Tax |
-$63.98 T
|
-$75.36 M
|
-$58.98 M
|
-$66.05 M
|
-$53.16 M
|
-$38.51 M
|
-$37.94 M
|
-$33.74 M
|
-$38.35 M
|
-$53.20 M
|
| Income Before Tax Ratio |
-45.26
|
0
|
0
|
0
|
0
|
0
|
-4.66
|
-10.93
|
-10.06
|
-17.85
|
| Income Tax Expense |
-$1.55 T
|
$2.80 K
|
$2.80 K
|
$2.80 K
|
$2.00 K
|
-$3.27 M
|
-$3.41 M
|
-$3.65 M
|
$501.50 K
|
$103.00 K
|
| Net Income |
-$62.42 T
|
-$75.37 M
|
-$58.98 M
|
-$66.05 M
|
-$53.16 M
|
-$35.24 M
|
-$34.52 M
|
-$30.09 M
|
-$38.85 M
|
-$53.30 M
|
| Net Income Ratio |
-44.16
|
0
|
0
|
0
|
0
|
0
|
-4.24
|
-9.74
|
-10.19
|
-17.89
|
| EPS |
-1.79 |
-4.06 |
-4.72 |
-6.23 |
-6.96 |
-13.47 |
-39.6 |
-194.8 |
-267.2 |
-587.2 |
| EPS Diluted |
-1.79 |
-4.06 |
-4.72 |
-6.23 |
-6.96 |
-13.47 |
-39.6 |
-85 |
-288 |
-587.2 |
| Weighted Average Shares Out |
$34.80 M
|
$18.55 M
|
$12.51 M
|
$10.60 M
|
$7.63 M
|
$3.63 M
|
$909.59 K
|
$154.00 K
|
$150.14 K
|
$90.00 K
|
| Weighted Average Shares Out Diluted |
$25.48 M
|
$18.55 M
|
$12.51 M
|
$10.60 M
|
$7.63 M
|
$3.63 M
|
$909.59 K
|
$354.03 K
|
$150.26 K
|
$107.58 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
